Enveric Biosciences, Inc. (ENVB)

Enveric Biosciences' stock price has significantly declined over the past six months and year. In January 2026, the company closed a registered direct offering. In March 2026, Enveric Biosciences secured a new U.S. patent for its EVM301 series of drug candidates. Also in March 2026, the company reported positive preclinical results for EB-003, leading to a premarket stock climb. In February 2026, Gilgamesh Pharmaceuticals withdrew a patent challenge against an Enveric patent.

There is no readily available information suggesting traditional demand seasonality for Enveric Biosciences' products and services. Demand is typically driven by medical need and regulatory approvals rather than seasonal patterns.

Enveric Biosciences, Inc. is a biotechnology company focused on developing neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders. The company utilizes its proprietary platform, "The Psybrary™," to create novel molecules. Its lead product candidate, EB-003, is a neuroplastogen in preclinical development for mental health disorders. EB-002 is a next-generation synthetic prodrug of psilocin for anxiety disorders. The EVM-301 series targets mental health outcomes, while the EVM401 series focuses on mental health and addiction. EV104 is a CBD + Celecoxib conjugate for osteoarthritis, and a cannabinoid-infused topical solution is in development for radiodermatitis. The company also develops cannabinoid conjugate molecules for pain and cancer.

Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts, with additional offices in Naples, Florida, and Calgary, Alberta, Canada.

Enveric Biosciences' reputation has been influenced by advancements in drug development and intellectual property. Positive media coverage has focused on EB-003. The withdrawal of a patent challenge by Gilgamesh Pharmaceuticals and the securing of new U.S. patents for the EVM301 series have also contributed positively.

Enveric Biosciences, Inc. is primarily owned by retail investors, followed by insiders and then institutional shareholders. The largest individual shareholder is Joseph Edward Tucker.